← Back
$LGND All transactions

LIGAND PHARMACEUTICALS INC

▼ SELL 10b5-1 Plan

$ Value

$69K

Shares

337

Price

$205

Filed

Apr 2

Insider

Name

Reardon Andrew

Title

CLO & Secretary

CIK

0001950232

Roles

Officer

Transaction Details

Transaction Date

2026-04-01

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

41,382

Footnotes

The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.4000 to $199.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4600 to $200.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.6000 to $201.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.6500 to $202.1900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.9900 to $203.7100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0100 to $204.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Filing Info

Accession No.

0002001011-26-000037

Form Type

4

Issuer CIK

0000886163

Reardon Andrew's History

Date Ticker Type Value
2026-04-01 LGND M $261K
2026-04-01 LGND $91K
2026-04-01 LGND $260K
2026-04-01 LGND $249K
2026-04-01 LGND $141K
2026-04-01 LGND $196K
2026-04-01 LGND $69K
2026-04-01 LGND M $0
2026-03-02 LGND A $0
2026-03-02 LGND A $0

Other Insiders at LGND (90d)

Insider Bought Sold Last
LAMATTINA JOHN L $434K 2026-03-06
KOZARICH JOHN W $94K 2026-04-01
Davis Todd C
Chief Executive Officer
2026-03-02
Sabba Stephen L $208K 2026-03-23
Espinoza Octavio
Chief Financial Officer
2026-03-02
Reardon Andrew
CLO & Secretary
$937K 2026-04-01